1. Updates in antineutrophil cytoplasmic antibody (ANCA)‐associated vasculitis for the ENT surgeon
- Author
-
Matthew L Coates and Marcos Martinez Del Pero
- Subjects
medicine.medical_specialty ,business.industry ,Diagnostic test ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ,ANCA-Associated Vasculitis ,medicine.disease ,ENT surgeon ,Otolaryngology ,Otorhinolaryngologic Diseases ,03 medical and health sciences ,0302 clinical medicine ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,otorhinolaryngologic diseases ,medicine ,Cocaine use ,Humans ,030223 otorhinolaryngology ,Intensive care medicine ,Head and neck ,Vasculitis ,Granulomatosis with polyangiitis ,business ,Anti-neutrophil cytoplasmic antibody - Abstract
ENT involvement is common in ANCA-associated vasculitis (AAV), particularly in GPA and EGPA. Early recognition and treatment is important for good outcomes, yet evidence suggests that UK ENT surgeons may not consistently recognise the early features of AAV, despite a similar incidence to vestibular schwannoma. AAV is a rapidly advancing field, with significant developments in the understanding of its pathogenesis, classification and treatment over the past decade. Relevant vasculitis mimics are also discussed with a particular focus on the increasing prevalence of vasculitis mimics driven by an increase in recreational cocaine use, as well as the emergence and reclassification of several other vasculitis mimics in the head and neck. This article reviews key recent updates in the vasculitis literature, with a particular focus on those relevant to recognition and diagnosis of AAV for the ENT surgeon. Strengths and limitations of relevant diagnostic testing are discussed, and a method of evaluation of patients with features of AAV presenting to ENT services is outlined.
- Published
- 2020
- Full Text
- View/download PDF